Aldeyra Therapeu (ALDX)

Jun 4, 2026, 8:45 AM EDT - 15 hours ago

Aldeyra Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:01 AM EDT - 2 days ago

Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

2026-05-27T09:59:56.000Z - 8 days ago

Shareholders Sue Aldeyra Therapeutics Over Dry Eye Drug Claims

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Aldeyra Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 6:39 PM EDT - 5 weeks ago

REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Aldeyra Therapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 5 weeks ago

Aldeyra Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 PM EDT - 6 weeks ago

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

Apr 20, 2026, 4:32 PM EDT - 6 weeks ago

ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

2026-03-18T10:12:28.000Z - 2 months ago

Aldeyra downgraded to Neutral from Buy at H.C. Wainwright

Mar 17, 2026, 4:33 PM EDT - 2 months ago

Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-17T13:11:09.000Z - 2 months ago

FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy

2026-03-17T13:10:25.000Z - 2 months ago

How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?

Mar 17, 2026, 8:36 AM EDT - 2 months ago

US FDA declines to approve Aldeyra's drug for eye disorder

Mar 17, 2026, 8:30 AM EDT - 2 months ago

Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

Feb 27, 2026, 7:00 AM EST - 3 months ago

Aldeyra Therapeutics Annual report: Q4 2025

Feb 25, 2026, 10:40 AM EST - 3 months ago

Aldeyra Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 7:01 AM EST - 3 months ago

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Dec 16, 2025, 6:00 PM EST - 6 months ago

Aldeyra Therapeutics Slides: Corporate Presentation

Dec 16, 2025, 8:00 AM EST - 6 months ago

Aldeyra Therapeutics Transcript: Study Update

Dec 16, 2025, 8:00 AM EST - 6 months ago

Aldeyra Therapeutics Press release: Study Update

2025-12-16T01:05:11.000Z - 6 months ago

Aldeyra announces PDUFA extension for Reproxalap

Dec 15, 2025, 7:30 PM EST - 6 months ago

Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

Dec 4, 2025, 8:30 AM EST - 6 months ago

Aldeyra Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 6:30 AM EST - 7 months ago

Aldeyra Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Aldeyra Therapeutics Transcript: R&D Day 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Aldeyra Therapeutics Press release: FY 2025

Nov 13, 2025, 8:00 AM EST - 7 months ago

Aldeyra Therapeutics Slides: FY 2025

2025-11-13T12:46:13.000Z - 7 months ago

Aldeyra expands RASP platform

Nov 13, 2025, 7:00 AM EST - 7 months ago

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Nov 11, 2025, 7:01 AM EST - 7 months ago

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 6, 2025, 7:00 AM EST - 7 months ago

Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET

Nov 6, 2025, 7:00 AM EST - 7 months ago

Aldeyra Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 4:00 PM EST - 7 months ago

Aldeyra Therapeutics Quarterly report: Q3 2025

2025-10-28T12:06:09.000Z - 7 months ago

Aldeyra ADX-629 achieves statistically significant improvement in liver function

Oct 28, 2025, 7:01 AM EDT - 7 months ago

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

2025-10-08T16:50:12.000Z - 8 months ago

Aldeyra price target raised to $7 from $6 at Jefferies

ABBV

Sep 8, 2025, 11:30 AM EDT - 9 months ago

Aldeyra Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:01 AM EDT - 9 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-28T11:16:06.000Z - 10 months ago

Aldeyra receives orphan designation from EMA for ADX-2191

Aug 28, 2025, 7:01 AM EDT - 10 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

2025-08-19T11:16:08.000Z - 10 months ago

Aldeyra granted fast track designation for ADX-2191 by FDA

Aug 19, 2025, 7:01 AM EDT - 10 months ago

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aug 13, 2025, 10:30 AM EDT - 10 months ago

Aldeyra Therapeutics Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 4:00 PM EDT - 10 months ago

Aldeyra Therapeutics Slides: Corporate Presentation

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Aldeyra Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 7:01 AM EDT - 10 months ago

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

2025-07-24T11:26:18.000Z - 11 months ago

Aldeyra receives orphan designation for ADX-2191 from EMA

Jul 24, 2025, 7:00 AM EDT - 11 months ago

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

2025-07-17T11:05:30.000Z - 11 months ago

Aldeyra announces FDA acceptance for review of reproxalap NDA

Jul 17, 2025, 7:00 AM EDT - 11 months ago

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

2025-06-26T11:11:17.000Z - 1 year ago

Aldeyra receives special protocol assessment agreement letter from FDA

Jun 26, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Slides: Corporate Presentation

2025-06-17T11:10:56.000Z - 1 year ago

Aldeyra resubmits topical ocular reproxalap NDA to FDA

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Jun 5, 2025, 4:20 PM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 7:01 AM EDT - 1 year ago

Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Quarterly report: Q1 2025

May 7, 2025, 4:07 PM EDT - 1 year ago

ALDX INVESTIGATION NOTICE: Aldeyra Therapeutics, Inc. Investors are Notified of the Pending Securities Investigation; Contact BFA Law

May 7, 2025, 8:46 AM EDT - 1 year ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

May 6, 2025, 3:48 PM EDT - 1 year ago

ALDX SECURITIES NEWS: Aldeyra Therapeutics, Inc. Investigation Could Allow Investors to Recover Losses; Contact BFA Law to Discuss

May 6, 2025, 8:00 AM EDT - 1 year ago

Aldeyra Therapeutics Transcript: Study Update

May 6, 2025, 8:00 AM EDT - 1 year ago

Aldeyra Therapeutics Slides: Study Update

2025-05-05T22:40:06.000Z - 1 year ago

Aldeyra’s reproxalap achieves primary endpoint in Phase 3 dry eye disease trial

May 5, 2025, 6:34 PM EDT - 1 year ago

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

May 5, 2025, 4:00 PM EDT - 1 year ago

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap

May 5, 2025, 3:38 PM EDT - 1 year ago

ALDX SECURITIES NOTICE: Suffer Losses on Aldeyra Therapeutics, Inc.? Investors are Alerted to Contact BFA Law about its Continuing Investigation

May 3, 2025, 7:18 AM EDT - 1 year ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

May 1, 2025, 8:08 AM EDT - 1 year ago

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) Investors with Losses are Urged to Contact BFA Law about its Investigation into the Company

Apr 30, 2025, 3:38 PM EDT - 1 year ago

ALDX ANNOUNCEMENT: Aldeyra Therapeutics, Inc. Investors may have been affected by Securities Violations - Contact BFA Law

Apr 29, 2025, 4:07 PM EDT - 1 year ago

ALDX NEWS: Aldeyra Therapeutics, Inc. is Being Investigated for Securities Violations - Investors are Alerted to Contact BFA Law